Antitope Enters Research Agreement with Annexon to Generate Novel Therapeutic Antibodies
Antitope Ltd recently announced it has entered a research agreement with Annexon to generate novel antibody therapeutics for the treatment of neurodegenerative diseases.
Under the terms of the agreement, Annexon will provide antibodies against specific components of the complement system, and Antitope will use its Composite Human Antibody technology to generate a series of fully humanized antibodies devoid of T cell epitopes and with a consequent low risk of clinical immunogenicity. Annexon will screen the Composite Human Antibodies provided by Antitope and select a lead antibody to take forward into further preclinical and clinical studies. Annexon’s most advanced program is for an orphan autoimmune neurological indication. The antibodies are expected to halt the progression of disease and allow the body to repair.
“This further agreement for Antitope’s Composite Human Antibody technology provides another opportunity for our technology to produce a better biopharmaceutical for the treatment of patients who despite years of research are still not receiving adequate treatment for their disease,” said Matt Baker, CSO of the PolyTherics group.
“We are very pleased to be working with Antitope to generate a fully humanized antibody against our novel target so that we can move it forward into advanced preclinical and clinical development for various neurodegenerative diseases,” added Arnon Rosenthal, Co-founder and Chairman of Annexon.
Antitope Limited is a subsidiary of PolyTherics Limited, a group which focuses on providing services and technologies to enable the development of better biopharmaceuticals. Antitope undertakes immunogenicity testing of antibodies and other proteins, engineering of antibodies and proteins to reduce their immunogenicity, and development of manufacturing cell lines. For more information, visit www.antitope.co.uk.
Annexon’s mission is to develop a new class of drugs to inhibit the complement system and halt the progression of multiple neurodegenerative disorders, including Alzheimer’s disease, glaucoma, Parkinson’s disease, spinal muscular atrophy, stroke, traumatic brain injury, multiple sclerosis, neuromyelitis optica, and peripheral nervous system diseases including Guillain-Barre syndrome and myasthenia gravis.
PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. For more information, visit www.polytherics.com.
Total Page Views: 1052
